Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:58:21.705Z.
Calculation as of: 2026-10-06T18:58:21.705Z.
Quote observation: 2026-10-06T18:55:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cae73e0f7d7453288b6b30bb28ae33caa2dcc4a3490ac3f0933bc7bc3ce0e433
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2025-03-31.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.91B
PS Ratio
19.41
TTM Avg
33.19
3Y Avg
53.74
5Y Avg
141.57
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.88B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 18.35 | 14.63 | 12.05 | 10.52 |
| Immunome, Inc. (IMNM)vs › | $1.90B | N/A | 284.94 | 122.88 | 115.64 |
| Zymeworks Inc. (ZYME)vs › | $1.90B | 51.05 | 22.83 | 14.69 | 15.20 |
| Azenta, Inc. (AZTA)vs › | $1.85B | 3.02 | 2.23 | 3.47 | 5.61 |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 0.48 | 0.49 | 0.90 | 1.14 |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.91B | 19.41 | 33.19 | 53.74 | 141.57 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | 0.93 | 0.93 | 4.78 | 7.17 |
| Novavax, Inc. (NVAX)vs › | $1.82B | 4.39 | 1.99 | 1.62 | 3.84 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2025-03-31 | 28.44 |
| 2025-03-28 | 28.55 |
| 2025-03-27 | 28.21 |
| 2025-03-26 | 28.38 |
| 2025-03-25 | 27.71 |
| 2025-03-24 | 28.32 |
| 2025-03-21 | 28.59 |
| 2025-03-20 | 27.87 |
| 2025-03-19 | 28.06 |
| 2025-03-18 | 28.31 |
| 2025-03-17 | 27.94 |
| 2025-03-14 | 27.91 |
| 2025-03-13 | 27.62 |
| 2025-03-12 | 29.47 |
| 2025-03-11 | 28.44 |
| 2025-03-10 | 25.57 |
| 2025-03-07 | 24.95 |
| 2025-03-06 | 24.33 |
| 2025-03-05 | 22.70 |
| 2025-03-04 | 21.03 |
| 2025-03-03 | 19.87 |
| 2025-02-28 | 19.68 |
| 2025-02-27 | 19.15 |
| 2025-02-26 | 19.10 |
| 2025-02-25 | 19.62 |
| 2025-02-24 | 20.31 |
| 2025-02-21 | 19.53 |
| 2025-02-20 | 19.31 |
| 2025-02-19 | 21.31 |
| 2025-02-18 | 21.33 |
| 2025-02-14 | 19.87 |
| 2025-02-13 | 20.32 |
| 2025-02-12 | 17.15 |
| 2025-02-11 | 16.41 |
| 2025-02-10 | 15.97 |
| 2025-02-07 | 15.80 |
| 2025-02-06 | 15.24 |
| 2025-02-05 | 15.00 |
| 2025-02-04 | 14.11 |
| 2025-02-03 | 13.18 |
| 2025-01-31 | 13.21 |
| 2025-01-30 | 13.72 |
| 2025-01-29 | 13.53 |
| 2025-01-28 | 12.85 |
| 2025-01-27 | 13.11 |
| 2025-01-24 | 12.69 |
| 2025-01-23 | 13.20 |
| 2025-01-22 | 13.36 |
| 2025-01-21 | 13.41 |
| 2025-01-17 | 13.39 |
| 2025-01-16 | 13.43 |
| 2025-01-15 | 13.52 |
| 2025-01-14 | 13.19 |
| 2025-01-13 | 13.21 |
| 2025-01-10 | 14.20 |
| 2025-01-08 | 14.48 |
| 2025-01-07 | 14.97 |
| 2025-01-06 | 14.99 |
| 2025-01-03 | 13.46 |
| 2025-01-02 | 12.19 |
| 2024-12-31 | 12.19 |
| 2024-12-30 | 12.19 |
| 2024-12-27 | 12.19 |
| 2024-12-26 | 12.07 |
| 2024-12-24 | 11.99 |
| 2024-12-23 | 12.19 |
| 2024-12-20 | 12.24 |
| 2024-12-19 | 12.19 |
| 2024-12-18 | 11.98 |
| 2024-12-17 | 13.21 |
| 2024-12-16 | 13.04 |
| 2024-12-13 | 13.82 |
| 2024-12-12 | 16.39 |
| 2024-12-11 | 16.87 |
| 2024-12-10 | 17.27 |
